Feedback / Questions
enoblituzumab (MGA271) - MacroGenics
vobramitamab duocarmazine (MGC018) - MacroGenics
https://www.globenewswire.com/news-release/2023/08/09/2722081/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-Second-Quarter-2023-Financial-Results.html
Aug 11, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next